International Journal of Hematology

, Volume 82, Issue 2, pp 137–142 | Cite as

Insulin-Like Growth Factor-Binding Protein 4 in Children with Acute Lymphoblastic Leukemia

  • Heike Wex
  • Dörte Ahrens
  • Bianka Hohmann
  • Antje Redlich
  • Uwe Mittler
  • Peter Vorwerk
Article

Abstract

Insulin-like growth factor-binding protein 4 (IGFBP-4) is a potent inhibitor of IGF-mediated cell proliferation. To investigate the functional relevance of IGFBP-4 in leukemia, we measured plasma IGFBP-4 levels and messenger RNA expression in leukemic cell clones of patients with acute lymphoblastic leukemia (ALL) and in control subjects. The IGFBP-4 levels of ALL patients at diagnosis were significantly lower than the levels of healthy control subjects. We evaluated the patients at diagnosis and after 33 days of chemotherapy and found plasma IGFBP-4 levels at day 33 to be significantly lower than the levels at diagnosis. There was no correlation of plasma IGFBP-4 level with age, sex, immunophenotype, or ALL risk group, and there was no correlation of IGFBP-4 level with plasma IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3 levels. Gene expression analysis of the leukemic blast population at diagnosis revealed that the leukemic clones did not significantly contribute to systemic IGFBP-4 levels. The decrease in plasma IGFBP-4 levels during chemotherapy represents an indirect effect, probably caused by the chemotherapeutic effects on IGFBP-4—expressing cells of the liver and other organs. In addition, IGFBP-4 gene expression was investigated in 13 human immune cell-related cell lines by reverse transcription-polymerase chain reaction analysis. IGFBP-4 was exclusively expressed in cell lines derived either from B-cells or from myelomonocytic cells, whereas IGFBP-4 was not expressed in T-cell lines.

Key words

Acute lymphoblastic leukemia IGFBP-4 Children 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities.Am J Physiol Endocrinol Metab. 2000;278:967–976.CrossRefGoogle Scholar
  2. 2.
    Wetterau LA, Moore MG, Lee KW, Shim ML, Cohen P. Novel aspects of the insulin-like growth factor binding proteins.Mol Genet Metab. 1999;68:161–181.CrossRefPubMedGoogle Scholar
  3. 3.
    Honda Y, Landale EC, Strong DD, Baylink DJ, Mohan S. Recombinant synthesis of insulin-like growth factor-binding protein-4 (IGFBP-4): development, validation, and application of a radioimmunoassay for IGFBP-4 in human serum and other biological fluids.J Clin Endocrinol Metab. 1996;81:1389–1396.PubMedGoogle Scholar
  4. 4.
    Zhou R, Diehl D, Hoeflich A, Lahm H, Wolf E. IGF-binding protein-4: biochemical characteristics and functional consequences.J Endocrinol. 2003;178:177–193.CrossRefPubMedGoogle Scholar
  5. 5.
    Kiefer MC, Schmid C, Waldvogel M, et al. Characterization of recombinant human insulin-like growth factor binding proteins 4, 5, and 6 produced in yeast.J Biol Chem. 1992;267:12692–12699.PubMedGoogle Scholar
  6. 6.
    Collett-Solberg PF, Cohen P. The role of the insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action.Endocrinol Metab Clin North Am. 1996;25:591–614.CrossRefPubMedGoogle Scholar
  7. 7.
    Lawrence JB, Oxvig C, Overgaard MT, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A.Proc NatlAcad Sci USA. 1999;96:3149–3153.CrossRefGoogle Scholar
  8. 8.
    Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis: a review of atherosclerosis and restenosis.Circ Res. 2000;86:125–130.CrossRefPubMedGoogle Scholar
  9. 9.
    Parker A, Gockerman A, Busby WH, Clemmons DR. Properties of an insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle cells.Endocrinology. 1995;136:2470–2476.CrossRefPubMedGoogle Scholar
  10. 10.
    Kubler B, Cowell S, Zapf J, Braulke T. Proteolysis of insulin-like growth factor binding proteins by a novel 50-kilodalton metallo-proteinase in human pregnancy serum.Endocrinology. 1998;139:1556–1563.CrossRefPubMedGoogle Scholar
  11. 11.
    Mazerbourg S, Zapf J, Bar RS, Brigstock DR, Monget P. Insulin-like growth factor (IGF)-binding protein-4 proteolytic degradation in bovine, equine, and porcine preovulatory follicles: regulation by IGFs and heparin-binding domain-containing peptides.Biol Reprod. 2000;63:390–400.CrossRefPubMedGoogle Scholar
  12. 12.
    Standker L, Braulke T, Mark S, et al. Partial IGF affinity of circulating N- and C-terminal fragments of human insulin-like growth factor binding protein-4 (IGFBP-4) and the disulfide bonding pattern of the C-terminal IGFBP-4 domain.Biochemistry. 2000;39:5082–5088.CrossRefPubMedGoogle Scholar
  13. 13.
    Miyakoshi N, Qin X, Kasukawa Y, et al. Systemic administration of insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) increases bone formation parameters in mice by increasing IGF bioavailability via an IGFBP-4 protease-dependent mechanism.Endocrinology. 2001;142:2641–2648.CrossRefPubMedGoogle Scholar
  14. 14.
    Mazerbourg S, Callebaut I, Zapf J, Mohan S, Overgaard M, Monget P. Up date on IGFBP-4: regulation of IGFBP-4 levels and functions, in vitro and in vivo.Growth Horm IGF Res. 2004;14:71–84.CrossRefPubMedGoogle Scholar
  15. 15.
    Wang J, Niu W, Witte DP, et al. Overexpression of insulin-like growth factor-binding protein-4 (IGFBP-4) in smooth muscle cells of transgenic mice through a smooth muscle α-actin-IGFBP-4 fusion gene induces smooth muscle hypoplasia.Endocrinology. 1998;139:2605–2614.CrossRefGoogle Scholar
  16. 16.
    Zhang M, Smith EP, Kuroda H, Banach W, Chernausek SD, Fagin JA. Targeted expression of a protease-resistant IGFBP-4 mutant in smooth muscle of transgenic mice results in IGFBP-4 stabilization and smooth muscle hypotrophy.J Biol Chem. 2002;277:21285–21290.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Miyakoshi N, Richman C, Qin X, Baylink DJ, Mohan S. Effects of recombinant insulin-like growth factor-binding protein-4 on bone formation parameters in mice.Endocrinology. 1999;140:5719–5728.CrossRefGoogle Scholar
  18. 18.
    Kelley KM, Oh Y, Gargosky SE, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics.Int J Biochem Cell Biol. 1996;28:619–637.CrossRefGoogle Scholar
  19. 19.
    Schmid C, Keller C, Gosteli-Peter M, Zapf J. Mitogenic and anti-apoptotic effects of insulin-like growth factor binding protein-6 in the human osteoblastic osteosarcoma cell line Saos-2/B-10.Biochem Biophys Res Commun. 1999;263:786–789.CrossRefGoogle Scholar
  20. 20.
    Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JM. Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells. JCell Biochem. 1999;75:652–664.CrossRefPubMedGoogle Scholar
  21. 21.
    Zumkeller W, Westphal M. The IGF/IGFBP system in CNS malignancy.Mol Pathol. 2001;54:227–229.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Mohnike K, Kluba U, Mittler U, Aumann V, Vorwerk P, Blum W. Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding protein-2 and -3 in children with acute lymphoblastic leukemia.Eur J Pediatr. 1996;155:81–86.CrossRefPubMedGoogle Scholar
  23. 23.
    Wex H, Vorwerk P, Mohnike K, et al. Elevated serum levels of IGFBP-2 found in children suffering from acute leukaemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone.Br J Cancer. 1998;78:515–520.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies: Working Group on Flow Cytometry and Image Analysis.Leukemia. 1996;10:877–895.PubMedGoogle Scholar
  25. 25.
    Mohan S, Bautista CM, Wergedal J, Baylink DJ. Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium: a potential local regulator of IGF action.Proc NatlAcad Sci USA. 1989;86:8338–8342.CrossRefGoogle Scholar
  26. 26.
    Giudice LC. Insulin-like growth factors and ovarian follicular development.Endocr Rev. 1992;13:641–669.PubMedGoogle Scholar
  27. 27.
    Singh P, Dai B, Dhruva B, Widen SG. Episomal expression of sense and antisense insulin-like growth factor (IGF)-binding protein-4 complementary DNA alters the mitogenic response of a human colon cancer cell line (HT-29) by mechanisms that are independent of and dependent upon IGF-I.Cancer Res. 1994;54:6563–6570.PubMedGoogle Scholar
  28. 28.
    Damon SE, Maddison L, Ware JL, Plymate SR. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation.Endocrinology.. 1998;139:3456–3464.CrossRefPubMedGoogle Scholar
  29. 29.
    Shimasaki S, Uchiyama F, Shimonaka M, Ling N. Molecular cloning of the cDNAs encoding a novel insulin-like growth factor-binding protein from rat and human.Mol Endocrinol. 1990;4:1451–1458.CrossRefPubMedGoogle Scholar
  30. 30.
    Smith WJ, Underwood LE, Clemmons DR. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF- binding proteins in children and adults.J Clin Endocrinol Metab. 1995;80:443–449.PubMedGoogle Scholar
  31. 31.
    Vorwerk P, Wex H, Hohmann B, Mohnike K, Schmidt U, Mittler U. Expression of components of the IGF signalling system in childhood acute lymphoblastic leukaemia.Mol Pathol. 2002;55:40–45.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Okazaki R, Riggs BL, Conover CA. Glucocorticoid regulation of insulin-like growth factor-binding protein expression in normal human osteoblast-like cells.Endocrinology. 1994;134:126–132.CrossRefPubMedGoogle Scholar
  33. 33.
    Fernandez-Celemin L,Thissen JP. Interleukin-6 stimulates hepatic insulin-like growth factor binding protein-4 messenger ribonucleic acid and protein.Endocrinology. 2001;142:241–248.CrossRefPubMedGoogle Scholar
  34. 34.
    Gersl V, Cerman J, Suba P, Mazurova Y, Hrdina R, Machackova J. IGF-I in experimental daunorubicin-induced cardiomyopathy in rabbits.Hum Exp Toxicol. 1999;18:154–161.CrossRefPubMedGoogle Scholar
  35. 35.
    van Doorn J, Cornelissen AJ, Buul-Offers SC. Plasma levels of insulin-like growth factor binding protein-4 (IGFBP-4) under normal and pathological conditions.Clin Endocrinol (Oxf). 2001;54:655–664.CrossRefGoogle Scholar
  36. 36.
    Neely EK, Smith SD, Rosenfeld RG. Human leukemic T and B lymphoblasts produce insulin-like growth factor binding proteins 2 and 4.Acta Endocrinol (Copenh). 1991;124:707–714.Google Scholar

Copyright information

© The Japanese Society of Hematology 2005

Authors and Affiliations

  • Heike Wex
    • 1
  • Dörte Ahrens
    • 1
  • Bianka Hohmann
    • 1
  • Antje Redlich
    • 1
  • Uwe Mittler
    • 1
  • Peter Vorwerk
    • 1
  1. 1.Department of Pediatric Hematology and OncologyUniversity Otto von GuerickeMagdeburgGermany

Personalised recommendations